Incidence of Neuromuscular Blockade Reappearance Post-Reversal with Glycopyrronium Bromide and Neostigmine Methylsulfate in General Anesthesia

The primary objective of this study is to determine the **incidence** of the reappearance of nondepolarizing neuromuscular block following reversal with **neostigmine** during general anesthesia. This is clinically relevant as it addresses the potential for residual neuromuscular blockade, which can lead to postoperative complications such as respiratory insufficiency and delayed recovery. Understanding the frequency and conditions under which this reappearance occurs can inform anesthetic management and improve patient safety during surgical procedures.

The clinical trial involves a study population comprising both **male** and **female** participants aged between 18 and 65 years. The participants are generally healthy, classified under ASA risk class 1-2, indicating a low risk of complications during anesthesia. The trial does not include a vulnerable population. Participants were selected based on specific criteria, including a **Body Mass Index (BMI)** of less than 35 kg/m². The sponsor has not provided information regarding the total number of participants. The study focuses on the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine, and lifestyle factors such as diet and physical activity were not specified as part of the selection criteria.

The clinical trial is designed to evaluate the **incidence of reappearance of nondepolarizing neuromuscular block** after reversal with **neostigmine**. This study is a Phase IV trial, characterized by a randomized, double-blind, controlled design, ensuring the reliability and validity of the results. The trial is expected to span from December 1, 2019, to December 31, 2026, providing a comprehensive assessment over several years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age (18-65 years), Body Mass Index (BMI) less than 35 kg/m², and ASA risk class 1-2. Following successful screening, participants will be randomized to receive the investigational product, **GLYCOSTIGMIN -injektioneste, liuos**, administered via **intravenous infusion**. The primary endpoint is to determine the incidence of muscle relaxation reappearance post-reversal with neostigmine.

Throughout the trial, participants will attend follow-up visits to monitor their response to the treatment and any potential adverse effects. The end-of-study visit will conclude the participant's involvement, where final assessments will be conducted to gather comprehensive data on the trial's primary objective. The expected length of participant involvement is contingent upon the trial's duration, with the possibility of early termination if adverse events occur or if the participant withdraws consent.

Participants will be closely monitored to ensure adherence to the protocol, and any deviations may result in early termination from the study. The trial's methodology and design are structured to provide robust data on the efficacy and safety of the treatment, contributing valuable insights into the management of neuromuscular blockade during general anesthesia.

The clinical trial involves the administration of **GLYCOSTIGMIN**, a **solution for injection** containing the active substances **glycopyrronium bromide** and **neostigmine methylsulfate**. This experimental medication is provided in the form of an injectable solution and is administered via **intravenous infusion**. The maximum daily dose and total dose amount are both limited to 1 ml, with the treatment period restricted to a single day. The pharmaceutical product is manufactured by Takeda Oy and is not formulated for pediatric use. The primary objective of the trial is to monitor the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine during general anesthesia.

In addition to the experimental treatment, the study may involve the use of standard-of-care therapies or comparator treatments as deemed necessary by the clinical protocol. The administration of the experimental medication and any additional treatments will be closely monitored to ensure participant compliance and to assess the efficacy and safety of the intervention. The trial does not involve the use of a placebo, and all substances used are of chemical origin. The study is designed to adhere to rigorous clinical standards to ensure the reliability and validity of the results.

The efficacy of the clinical trial will be assessed by evaluating the **incidence of reappearance of nondepolarizing neuromuscular block** after reversal with neostigmine. This primary endpoint will be measured to determine the effectiveness of the intervention in preventing the recurrence of neuromuscular blockade during general anesthesia. The trial aims to monitor this specific outcome to ensure the reliability and safety of the treatment protocol involving the use of neostigmine methylsulfate and glycopyrronium bromide.